A clinical trial has shown that obese gout patients will benefit from diet and lowered body weight, but weight loss was not associated with beneficial effects on serum urica acid (SUA), fatigue or pain.
Weight loss is commonly recommended as management strategy for gout patients. This trial investigated the effect of an intensive dietary intervention on body weight and gout outcomes in patients with obesity and gout.
Dr. John Cush RheumNow
2 years 7 months ago
There is a dose, duration and recency-dependent relationship between previous GC use and MACE. GC doses 5mg/day, durations of 30 days, and use one year prior to MACE were all associated with an increased risk of MACE, Wallace B Abst#2430 #ACR23 #ACRBest https://t.co/RdLUvW3W7v https://t.co/CcQXQYwu7J
Dr. John Cush RheumNow
2 years 7 months ago
Marketscan claims data shows Frailty as predictor for serious infxn in RA pts Rx w/ b/tsDMARDs. Among 57,980 RA pts (age 48 yrs), 6% were "frail" - this assoc w/ increased risk of serious infections (aHR 1.5) & inpatient hosp (1.4)https://t.co/cvcqE3KQmV https://t.co/We9uwMdt5Y
Dr. John Cush RheumNow
2 years 7 months ago
Anti-TNF mAbs, JAKi & anti-IL17 Rx appear protective against anterior Uveitis in AxSpA pts. Network Metanalysis of 44 trials, AU IR -TNF mAb: 4.1, ETN: 5.4, IL17i: 2.8, JAKi: 1.5, & placebo: 10.8. AU risk: TNFi < JAKi < IL-17i < ETN << PBO https://t.co/uRYKmtUdsZ https://t.co/5XdBVDfgYV
Dr. John Cush RheumNow
2 years 7 months ago
Chinese Phase 2b RCT of telitacicept (TACI-Fc fusion protein inhibits both BAFF & APRIL) 3 doses vs PBO in 249 active SLE pts. Wk 48 SRI-4 response favored TELI (76% 240 mg, 68% 160 mg, 71% 80 mg vs 34% w/ PBO (all p<0.001) https://t.co/fz4W1le4Db https://t.co/0mTC4gQcdr
Dr. John Cush RheumNow
2 years 7 months ago
Congratulations to Professor Paul Emery OBE on being named CBE: Commander of the Most Excellent Order of the British Empire for his research and advances in rheumatology. He is the Versus Arthritis Professor of Rheumatology, Leeds Institute https://t.co/xeJu05q3q8 https://t.co/VvKmHHf0iv
Dr. John Cush RheumNow
2 years 7 months ago
Dr. Sidney Wolfe, longtime US consumer health watchdog & advocate for affordable care & oversight of drug safety died on 1/1/24 of brain cancer at age 86. Dr. Wolf once ran the Health Research Group at Public Citizen, a Wash, DC consumer advocacy group https://t.co/e4lyDglx3n https://t.co/VyLMXJi4ZZ
Sarcopenia commonly has been linked to aging and arthritis and contributes significantly to quality of life and outcomes, but the association between sarcopenia and OA has not been well established.
One major subgroup of patients with interstitial lung disease (ILD) arising from polymyositis/dermatomyositis (PM/DM) survived significantly longer when serum levels of interferon-λ3 were relatively low, researchers found.
Dr. John Cush RheumNow
2 years 7 months ago
Best of 2023: New ACR RA-ILD Treatment Guidelines – What Were They Smoking!?
Rheumatoid arthritis related interstitial lung disease (RA-ILD) is common, with symptomatic RA-ILD affecting approximately 8% of RA patients.
https://t.co/6RFBjVkmXj https://t.co/Qvquu7ruKY
Dr. John Cush RheumNow
2 years 7 months ago
AutoAbs in poly/dermatomyositis - ANA+ 50% to 80%, but not helpful in Dx. Look for MSA Abs - espec antisynthetase ABs (anti-Jo-1), but also newer Abs: MDA-5, TIFF-1 gamma, NXP-2 (to be discussed #RNL24 Dr. Christopher-Stine) https://t.co/l46JHMWJby https://t.co/rZco5BMUJ5 https://t.co/2K9bidzLpt
Dr. John Cush RheumNow
2 years 7 months ago
Global temporal trends in MSK disorders in women of childbearing age increasing in138 countries, 24 decreasing & 42 w. flat trends. In 2019, the prevalence was 354 million w/ India, with China, USA, Indonesia & Brazil highest w/ 51% of global prevalence https://t.co/8nn4lTtNU2 https://t.co/BdkR3aXsZO
Dr. John Cush RheumNow
2 years 7 months ago
Best of 2023: Treatment and Management of Neuropsychiatric Lupus
On the first day of ACR State of the Art conference in Orlando, Florida, Dr. Michelle Petri reviewed the treatment and management of neuropsychiatric lupus.
https://t.co/0MXAtkDUmQ https://t.co/ZYuLniETnP
Dr. John Cush RheumNow
2 years 7 months ago
Best of 2023: Does Biologic Treatment in Psoriasis Reduce the Risk of Psoriatic Arthritis?
https://t.co/9xn7lvxPiG https://t.co/PFYUISEKLe
